Tesamorelin

FDA Approved

Tesamorelin

Category
Growth Hormone
Aliases
Egrifta, Egrifta SV
Administration
Subcutaneous injection (once daily)

How it works

  1. Binds GHRH receptors on pituitary somatotrophs

    It attaches to pituitary cells and tells them to release growth hormone.

  2. Stimulates pulsatile, physiologic growth hormone release

    It triggers growth hormone release in your body's natural rhythmic pattern rather than a constant flood.

  3. Selectively reduces visceral adipose tissue

    Clinically, it specifically shrinks visceral fat — the fat around your organs — more than fat elsewhere.

  4. Increases IGF-1 downstream via hepatic signaling

    It raises IGF-1, the hormone that carries out much of growth hormone's tissue-building work.

Result

A measurable reduction in visceral (deep abdominal) fat, the only FDA-approved outcome of this kind among growth-hormone-stimulating peptides. In clinical use, this shows up as a visibly flatter abdomen over several months, distinct from overall body weight change.